Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-hour versus 24-hour magnesium sulfate regimen for severe preeclampsia
PACTR202304555642144Phase 3Not yet recruiting
- Sponsor
- Samah Mohammed Ahmed Hussein
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of magnesium sulfate in preeclampsia (2 arms), sponsored by Samah Mohammed Ahmed Hussein. Primary endpoints: Occurrence of convulsions after magnesium sulfate therapy and Maternal adverse effects. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
magnesium sulfate
03
Conditions
preeclampsia
Beyond the preview
Go deeper on PACTR202304555642144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202304555642144.